251 related articles for article (PubMed ID: 34748021)
1. Association Between SGLT2 Inhibitors vs DPP-4 Inhibitors and Risk of Pneumonia Among Patients With Type 2 Diabetes.
Au PCM; Tan KCB; Cheung BMY; Wong ICK; Wong Y; Cheung CL
J Clin Endocrinol Metab; 2022 Mar; 107(4):e1719-e1726. PubMed ID: 34748021
[TBL] [Abstract][Full Text] [Related]
2. Association Between SGLT2 Inhibitors vs DPP4 Inhibitors and Renal Outcomes Among Patients With Type 2 Diabetes.
Au PCM; Tan KCB; Cheung BMY; Wong ICK; Li HL; Cheung CL
J Clin Endocrinol Metab; 2022 Jun; 107(7):e2962-e2970. PubMed ID: 35303075
[TBL] [Abstract][Full Text] [Related]
3. Association of Sodium-Glucose Cotransporter 2 Inhibitor vs Dipeptidyl Peptidase-4 Inhibitor Use With Risk of Incident Obstructive Airway Disease and Exacerbation Events Among Patients With Type 2 Diabetes in Hong Kong.
Au PCM; Tan KCB; Lam DCL; Cheung BMY; Wong ICK; Kwok WC; Sing CW; Cheung CL
JAMA Netw Open; 2023 Jan; 6(1):e2251177. PubMed ID: 36648944
[TBL] [Abstract][Full Text] [Related]
4. Safety of sodium-glucose co-transporter-2 inhibitors on amputation across categories of baseline cardiovascular disease and diuretics use in patients with type 2 diabetes.
Park S; Jeong HE; Bea S; Yu OHY; Cho YM; You SC; Man KKC; Shin JY
Diabetes Obes Metab; 2023 Nov; 25(11):3248-3258. PubMed ID: 37503763
[TBL] [Abstract][Full Text] [Related]
5. Association of adverse respiratory events with sodium-glucose cotransporter 2 inhibitors versus dipeptidyl peptidase 4 inhibitors among patients with type 2 diabetes in South Korea: a nationwide cohort study.
Jeong HE; Park S; Noh Y; Bea S; Filion KB; Yu OHY; Jang SH; Cho YM; Yon DK; Shin JY
BMC Med; 2023 Feb; 21(1):47. PubMed ID: 36765407
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Dipeptidyl Peptidase-4 Inhibitor on the Risks of New-Onset Atrial Fibrillation, Stroke and Mortality in Diabetic Patients: A Propensity Score-Matched Study in Hong Kong.
Lee S; Zhou J; Leung KSK; Wai AKC; Jeevaratnam K; King E; Liu T; Wong WT; Chang C; Wong ICK; Cheung BMY; Tse G; Zhang Q
Cardiovasc Drugs Ther; 2023 Jun; 37(3):561-569. PubMed ID: 35142921
[TBL] [Abstract][Full Text] [Related]
7. Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.
Melzer Cohen C; Schechter M; Rozenberg A; Yanuv I; Sehtman-Shachar DR; Fishkin A; Rosenzweig D; Chodick G; Karasik A; Mosenzon O
Clin J Am Soc Nephrol; 2023 Sep; 18(9):1153-1162. PubMed ID: 37382938
[TBL] [Abstract][Full Text] [Related]
8. Comparative effectiveness of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors on liver function in patients with type 2 diabetes in Japan: A real-world data analysis.
Takahashi H; Asakawa K; Kosakai Y; Lee T; Rokuda M
Diabetes Obes Metab; 2024 Mar; 26(3):997-1007. PubMed ID: 38086547
[TBL] [Abstract][Full Text] [Related]
9. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
[TBL] [Abstract][Full Text] [Related]
10. Risk of sepsis and pneumonia in patients initiated on SGLT2 inhibitors and DPP-4 inhibitors.
Wu MZ; Chandramouli C; Wong PF; Chan YH; Li HL; Yu SY; Tse YK; Ren QW; Yu SY; Tse HF; Lam CSP; Yiu KH
Diabetes Metab; 2022 Nov; 48(6):101367. PubMed ID: 35753654
[TBL] [Abstract][Full Text] [Related]
11. Comparative Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for Recurrent Gout Flares and Gout-Primary Emergency Department Visits and Hospitalizations : A General Population Cohort Study.
McCormick N; Yokose C; Wei J; Lu N; Wexler DJ; Aviña-Zubieta JA; De Vera MA; Zhang Y; Choi HK
Ann Intern Med; 2023 Aug; 176(8):1067-1080. PubMed ID: 37487215
[TBL] [Abstract][Full Text] [Related]
12. Effect of SGLT2 inhibitors versus DPP4 inhibitors or GLP-1 agonists on diabetic foot-related extremity amputation in patients with T2DM: A meta-analysis.
Du Y; Bai L; Fan B; Ding H; Ding H; Hou L; Ma H; Xing N; Wang F
Prim Care Diabetes; 2022 Feb; 16(1):156-161. PubMed ID: 34930687
[TBL] [Abstract][Full Text] [Related]
13. Comparative Safety of Sodium-Glucose Cotransporter 2 Inhibitors Versus Dipeptidyl Peptidase 4 Inhibitors and Sulfonylureas on the Risk of Diabetic Ketoacidosis.
Dawwas GK; Flory JH; Hennessy S; Leonard CE; Lewis JD
Diabetes Care; 2022 Apr; 45(4):919-927. PubMed ID: 35147696
[TBL] [Abstract][Full Text] [Related]
14. Sodium-glucose co-transporter-2 inhibitors are associated with kidney benefits at all degrees of albuminuria: A retrospective cohort study of adults with diabetes.
Fujita KK; Ye F; Collister D; Klarenbach S; Campbell DJT; Chew DS; Quinn AE; Ronksley P; Lau D
Diabetes Obes Metab; 2024 Feb; 26(2):699-709. PubMed ID: 37997302
[TBL] [Abstract][Full Text] [Related]
15. Meta-analysis on the efficacy and safety of SGLT2 inhibitors and incretin based agents combination therapy vs. SGLT2i alone or add-on to metformin in type 2 diabetes.
Zhou Y; Geng Z; Wang X; Huang Y; Shen L; Wang Y
Diabetes Metab Res Rev; 2020 Feb; 36(2):e3223. PubMed ID: 31642583
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in older adults with type 2 diabetes: A nationwide population-based study.
Han SJ; Ha KH; Lee N; Kim DJ
Diabetes Obes Metab; 2021 Mar; 23(3):682-691. PubMed ID: 33236515
[TBL] [Abstract][Full Text] [Related]
17. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
[TBL] [Abstract][Full Text] [Related]
18. Sodium-glucose cotransporter-2 inhibitors and the risk of gout in patients with type 2 diabetes mellitus: A propensity-score-matched, new-user design study with an active comparator using the IQVIA Medical Research Data UK database.
Subramanian A; Gokhale K; Sainsbury C; Nirantharakumar K; Toulis KA
Diabetes Obes Metab; 2023 Jan; 25(1):156-165. PubMed ID: 36056476
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Benefits With Favorable Renal, Amputation and Hypoglycemic Outcomes of SGLT-2 Inhibitors in Type 2 Diabetes From the Asian Perspective: A Population-Based Cohort Study and Systematic Review.
Yang CT; Peng ZY; Chen YC; Ou HT; Kuo S
Front Endocrinol (Lausanne); 2022; 13():836365. PubMed ID: 35330915
[TBL] [Abstract][Full Text] [Related]
20. Exposure to dipeptidyl-peptidase 4 inhibitors and the risk of pneumonia among people with type 2 diabetes: Retrospective cohort study and meta-analysis.
Morieri ML; Bonora BM; Longato E; Di Camilo B; Sparacino G; Tramontan L; Avogaro A; Fadini GP
Diabetes Obes Metab; 2020 Oct; 22(10):1925-1934. PubMed ID: 32691492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
